Literature DB >> 21838221

EGFR-targeted magnetic nanoparticle heaters kill cancer cells without a perceptible temperature rise.

Mar Creixell1, Ana C Bohórquez, Madeline Torres-Lugo, Carlos Rinaldi.   

Abstract

It is currently believed that magnetic nanoparticle heaters (MNHs) can kill cancer cells only when the temperature is raised above 43 °C due to energy dissipation in an alternating magnetic field. On the other hand, simple heat conduction arguments indicate that in small tumors or single cells the relative rates of energy dissipation and heat conduction result in a negligible temperature rise, thus limiting the potential of MNHs in treating small tumors and metastatic cancer. Here we demonstrate that internalized MNHs conjugated to epidermal growth factor (EGF) and which target the epidermal growth factor receptor (EGFR) do result in a significant (up to 99.9%) reduction in cell viability and clonogenic survival in a thermal heat dose dependent manner, without the need for a perceptible temperature rise. The effect appears to be cell type specific and indicates that magnetic nanoparticles in alternating magnetic fields may effectively kill cancer cells under conditions previously considered as not possible.
© 2011 American Chemical Society

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21838221     DOI: 10.1021/nn201822b

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  74 in total

1.  Optically stable biocompatible flame-made SiO2-coated Y2O3:Tb3+ nanophosphors for cell imaging.

Authors:  Georgios A Sotiriou; Davide Franco; Dimos Poulikakos; Aldo Ferrari
Journal:  ACS Nano       Date:  2012-05-04       Impact factor: 15.881

2.  Controlled cell death by magnetic hyperthermia: effects of exposure time, field amplitude, and nanoparticle concentration.

Authors:  L Asín; M R Ibarra; A Tres; G F Goya
Journal:  Pharm Res       Date:  2012-02-24       Impact factor: 4.200

Review 3.  Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies.

Authors:  Frederik Soetaert; Preethi Korangath; David Serantes; Steven Fiering; Robert Ivkov
Journal:  Adv Drug Deliv Rev       Date:  2020-06-27       Impact factor: 15.470

Review 4.  Can nanomedicines kill cancer stem cells?

Authors:  Yi Zhao; Daria Y Alakhova; Alexander V Kabanov
Journal:  Adv Drug Deliv Rev       Date:  2013-10-10       Impact factor: 15.470

5.  Nanoparticle-based local translation reveals mRNA as a translation-coupled scaffold with anchoring function.

Authors:  Shunnichi Kashida; Dan Ohtan Wang; Hirohide Saito; Zoher Gueroui
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-19       Impact factor: 11.205

6.  Diagnostic and Therapeutic Nanomedicine.

Authors:  Jinmyoung Joo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Comparison of magnetic nanoparticle and microwave hyperthermia cancer treatment methodology and treatment effect in a rodent breast cancer model.

Authors:  Alicia A Petryk; Andrew J Giustini; Rachel E Gottesman; B Stuart Trembly; P Jack Hoopes
Journal:  Int J Hyperthermia       Date:  2013-12       Impact factor: 3.914

8.  Determining iron oxide nanoparticle heating efficiency and elucidating local nanoparticle temperature for application in agarose gel-based tumor model.

Authors:  Rhythm R Shah; Alexander R Dombrowsky; Abigail L Paulson; Margaret P Johnson; David E Nikles; Christopher S Brazel
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2016-05-21       Impact factor: 7.328

9.  Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance.

Authors:  Mar Creixell; Nicholas A Peppas
Journal:  Nano Today       Date:  2012-08-01       Impact factor: 20.722

10.  Monitoring nanoparticle-mediated cellular hyperthermia with a high-sensitivity biosensor.

Authors:  Amarnath Mukherjee; Mark Castanares; Mohammad Hedayati; Michele Wabler; Bruce Trock; Prakash Kulkarni; Ronald Rodriguez; Robert H Getzenberg; Theodore L DeWeese; Robert Ivkov; Shawn E Lupold
Journal:  Nanomedicine (Lond)       Date:  2014-12       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.